OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
The OncLive Insider app is live!CME Opportunities
Specialty
View MoreBreast CancerLung CancerGastrointestinal CancerGenitourinary CancersOvarian CancerProstate CancerMelanoma & Skin CancerMCLMPNCAR T-cell TherapyChronic Lymphocytic LeukemiaGynecologic OncologyHematologic OncologyImmuno-OncologyMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
PartnersPublications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker ConsortiumSubscribe
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • The OncLive Insider app is live!
  • CME Opportunities
SpecialtySee All >
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Ovarian Cancer
  • Prostate Cancer
  • Melanoma & Skin Cancer
  • MCL
  • MPN
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gynecologic Oncology
  • Hematologic Oncology
  • Immuno-Oncology
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Sangeetha Palakurthi, PhD

  1. home

Articles

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

October 19th 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

April 21st 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.